CXCR4 and plasma cell myeloma: F50067, a humanized mAb targeting CXCR4, demonstrated preclinical anti-tumor activity in multiple myeloma, and phase I study was performed to assess the safety and efficacy of F50067 alone and in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (21).